Abstract:Monkeypox (now Mpox), a zoonotic disease caused by the monkeypox virus (MPXV) is an emerging threat to global health. In the time span of only six months, from May to October 2022, the number of MPXV cases breached 80,000 and many of the outbreaks occurred in locations that had never previously reported MPXV. Currently there are no FDA-approved MPXV-specific vaccines or treatments, therefore, finding drugs to combat MPXV is of utmost importance. The A42R profilin-like protein of the MPXV is involved in cell development and motility making it a critical drug target. A42R protein is highly conserved across orthopoxviruses, thus A42R inhibitors may work for other family members. This study sought to identify potential A42R inhibitors for MPXV treatment using computational approaches. The energy minimized 3D structure of the A42R profilin-like protein (PDB ID: 4QWO) underwent virtual screening using a library of 36,366 compounds from Traditional Chinese Medicine (TCM), AfroDb, and PubChem databases as well as known inhibitor tecovirimat via AutoDock Vina. A total of seven compounds comprising PubChem CID: 11371962, ZINC000000899909, ZINC000001632866, ZINC000015151344, ZINC000013378519, ZINC000000086470, and ZINC000095486204, predicted to have favorable binding were shortlisted. Molecular docking suggested that all seven proposed compounds have higher binding affinities to A42R (–7.2 to –8.3 kcal/mol) than tecovirimat (–6.7 kcal/mol). This was corroborated by MM/PBSA calculations, with tecovirimat demonstrating the highest binding free energy of –68.694 kJ/mol (lowest binding affinity) compared to the seven shortlisted compounds that ranged from –73.252 to –97.140 kJ/mol. Furthermore, the 7 compounds in complex with A42R demonstrated higher stability than the A42R-tecovirimat complex when subjected to 100 ns molecular dynamics simulations. The protein-ligand interaction maps generated using LigPlot+ suggested that residues Met1, Glu3, Trp4, Ile7, Arg127, Val128, Thr131, and Asn133 are important for binding. These seven compounds were adequately profiled to be potential antivirals via PASS predictions and structural similarity searches. All seven potential lead compounds were scored Pa > Pi for antiviral activity while ZINC000001632866 and ZINC000015151344 were predicted as poxvirus inhibitors with Pa values of 0.315 and 0.215, and Pi values of 0.052 and 0.136, respectively. Further experimental validations of the identified lead compounds are required to corroborate their predicted activity. These seven identified compounds represent solid footing for development of antivirals against MPXV and other orthopoxviruses.

Antiviral activity of Tecovirimat against Mpox virus clades 1a, 1b, 2a and 2b

MECHANISMS OF TECOVIRIMAT ANTIVIRAL ACTIVITY AND POXVIRUS RESISTANCE

Treatment Efficacy of Cidofovir and Brincidofovir against Clade II Monkeypox Virus isolates

Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

Breaking Barriers: Current Advances and Future Directions in Mpox Therapy

The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?

Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak - Los Angeles County, June 2022-January 2023

Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023

In silico identification of potential phytochemical inhibitors for mpox virus: molecular docking, MD simulation, and ADMET studies

VP37 Protein Inhibitors for Mpox Treatment: Highlights on Recent Advances, Patent Literature, and Future Directions

Identifying potential monkeypox virus inhibitors: an in silico study targeting the A42R protein

Early Tecovirimat Treatment for Mpox Disease Among People With HIV

Supervised Screening of Tecovirimat-like Compounds As Potential Inhibitors for the Monkeypox Virus E8L Protein

Comparative Analysis of 2022 Outbreak MPXV and Previous Clade II MPXV

Tecovirimat for Mpox—Promise and Limitations

Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses

MPXV Infects Human PBMCs in a Type I Interferon-Sensitive Manner

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment

Novel derivatives of BCV and (S)-HPMPA inhibit orthopoxviruses and human adenoviruses more potently than BCV

Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes